Education
About Us
Working with TipRanks
Follow Us
ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
RESEARCH TOOLSreports
ABVC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $1.73
Previous CloseN/A
Volume151.09K
Average Volume (3M)346.25K
Market Cap
$11.87M
Enterprise Value$10.00M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$848.35K
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding12,975,492
10 Day Avg. Volume471,631
30 Day Avg. Volume346,250
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.56
Price to Cash Flow (P/CF)13.00
P/FCF Ratio4.80
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-66.86
Enterprise Value/Ebitda-1.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
ABVC BioPharma, Inc. News
PremiumCompany Announcements
ABVC BioPharma Delays Yearly Report Filing
PremiumCompany Announcements
ABVC BioPharma Releases Corporate Presentation Update
---
Ownership Overview
―
Insiders
0.97% Mutual Funds
1.23% Other Institutional Investors
97.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.40 and its highest was $1.73 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $11.87M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 225 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
Currently, no data Available
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 12,975,492 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
---
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
---
ABVC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Plus Therapeutics
―
Ocular Therapeutix
―
Cellectar Biosciences
―
Citius Pharmaceuticals
―
Aprea Therapeutics
―
---